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SUMMARY
Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second most lethal cancer 
worldwide. HCC prediction and prevention in cirrhosis are key unmet medical needs. Here we 
have established an HCC risk gene signature applicable to all major HCC etiologies: hepatitis B/C, 
alcohol, and non-alcoholic steatohepatitis. A transcriptome meta-analysis of >500 human 
cirrhotics revealed global regulatory gene modules driving HCC risk and lysophosphatidic acid 
pathway as a central chemoprevention target. Pharmacological inhibition of the pathway in vivo 
reduced tumors and reversed the gene signature, which was verified in organotypic ex vivo culture 
of patient-derived fibrotic liver tissues. These results demonstrate the utility of clinical organ 
transcriptome to enable a strategy, reverse-engineering precision cancer prevention.
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Prevention of disease progression has drastically improved patient mortality in several 
chronic diseases such as cerebro- and cardiovascular diseases, although cancer prevention 
has been a challenging task as evidenced by its almost unchanged mortality over the past 
several decades (Vogelstein et al., 2013). The major bottleneck remains the elusive 
mechanisms of carcinogenesis, and the difficulty in clinically verifying animal model-based 
findings due to the requirement for long-term monitoring of large number of cancer-free, 
asymptomatic individuals. In addition, the scarcity of cancer risk biomarkers hampers 
identification of high-risk populations that could be used to design clinical trials with 
practically feasible sample size and follow-up time (Hoshida et al., 2014). To overcome the 
obstacles for discovery of clinically relevant cancer chemoprevention targets and therapies, 
we have employed a “reverse engineering” approach, where cancer initiation-driving targets 
are first defined based on long-term clinical follow-up in multiple patient cohorts, and 
subsequently validated by experimental systems.
Liver cirrhosis is the terminal stage of chronic inflammatory and fibrotic liver diseases, and a 
distinct risk factor for developing hepatocellular carcinoma (HCC), the major histological 
type of liver cancer and the second leading cause of cancer mortality worldwide (Hoshida et 
al., 2014). Established cirrhosis is a strongly precancerous state with annual HCC incidence 
up to 8%, and complete removal of HCC tumors does not prevent subsequent, repeated de 
novo HCC development from remnant cirrhotic livers (70% recurrence rate within 5 years of 
surgical resection), resulting in incurable advanced-stage diseases and a persistently dismal 
prognosis (5-year survival rate generally less than 15%) (Forner et al., 2012). The strong 
carcinogenic “field effect” in the cirrhotic liver clearly indicates that cirrhosis is a rational 
target to explore cancer chemoprevention biomarkers and therapies (Hoshida et al., 2014). 
However, the diversity of etiological agents, namely hepatitis C virus (HCV), hepatitis B 
virus (HBV), alcohol abuse, and non-alcoholic fatty liver diseases (NAFLD)/non-alcoholic 
steatohepatitis (NASH), has precluded identification of broadly applicable cancer risk 
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biomarkers that could potentially salvage the HCC surveillance program that has collapsed 
due to the vast size of the cirrhotic population (Davila et al., 2010).
To address this unmet need and establish the first step of our “reverse-engineering” 
approach, we have identified and validated a 186-gene HCC risk-predictive signature in liver 
tissues (HCC risk gene signature), which was stable across multiple sampling sites in the 
liver and not affected by presence or absence of HCC tumor in the liver, in multiple 
independent patient cohorts enrolled from Asia, Europe, and the U.S., mainly affected by 
HCV infection and clinically followed for up to 23 years (Hoshida et al., 2008; Hoshida et 
al., 2013; King et al., 2015). The gene signature successfully monitored the HCC 
chemopreventive effect of an FDA-approved small molecule epidermal growth factor (EGF) 
pathway inhibitor, erlotinib, in multiple rodent models of cirrhosis-driven HCC (Fuchs et al., 
2014), which led to initiation of a proof-of-concept, biomarker-guided cancer 
chemoprevention clinical trial (ClinicalTrials.gov, NCT02273362). However, it is still 
undetermined whether the gene signature is universally applicable beyond HCV. Moreover, 
adverse effects of erlotinib limit its wide-spread use as a preventive medicine and therefore 
indicate the necessity to further identify better HCC chemoprevention targets. Here our goals 
were to establish the clinical HCC risk gene signature assay in all major HCC etiologies, 
elucidate global molecular regulatory networks in cirrhotic liver for HCC chemoprevention 
target discovery, and to demonstrate the feasibility of fast-track, simultaneous identification 
of cancer chemoprevention targets, drugs, and biomarkers ready for clinical assessment.
RESULTS
Pan-etiology HCC risk gene signature
In our previous studies, the HCC risk gene signature has been validated for its association 
with future cancer risk in fibrotic/cirrhotic patients mainly affected by chronic HCV 
infection (Figure S1A, Cohort 1–4, n=668 in total) (Hoshida et al., 2008; Hoshida et al., 
2013; King et al., 2015). Reanalysis of publicly available datasets of patient series affected 
with HBV, alcohol abuse, and NASH showed significant association of the signature with 
clinical outcome or disease severity (Figure S1B). To verify the findings with a clinically 
applicable assay, we implemented a reduced version of the 186-gene HCC risk gene 
signature bioinformatically defined in our recent study (32-gene signature) (King et al., 
2015) in an FDA-approved digital transcript counting technology (Elements assay, 
NanoString). Technical validation demonstrated a high reproducibility of the gene 
expression measurements with the assay (Figure S1C). The assay was tested in liver tissues 
from an independent cohort of surgically-treated, early-stage HCC patients (n=263, Cohort 
5) related to either of HCV, HBV, alcohol, or NAFLD/NASH, and followed for up to 23 
years (Table S1). Complete removal of the tumors was histologically and radiologically 
confirmed. Recurrence hazard plot showed that the recurrences are dominantly de novo 
recurrence rather than dissemination/metastasis of the primary tumors (see Figure S1D for 
details). With the gene signature-based prediction, 57 (22%), 148 (56%), and 58 (22%) 
patients were classified into high-, intermediate-, and low-risk groups, respectively (Figure 
1A). Concordant prognostic prediction between permutation of genome-wide and only 
signature genes was observed in our previously generated genome-wide transcriptome 
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profiles (Cohort 1, Figure S1E). These risk groups were strikingly associated with de novo 
HCC recurrence (Figure 1B). Interestingly, the HCC risk gene signature quantitatively 
depicted the relative risk status of the liver according to etiology (Figure 1A). HBV-infected 
liver showed relatively lower risk status (p<0.001, Kolmogorov-Smirnov test) consistent 
with the clinical observation that HBV-related HCC is associated with less frequent post-
surgical/ablative HCC development compared to HCV in both Western and Eastern patient 
cohorts (Franssen et al., 2014; Minami et al., 2015). In contrast, NAFLD/NASH-affected 
livers accumulated on the higher risk side (p<0.001) despite the lowest frequency of 
established cirrhosis (23% in NAFLD, 21% in NASH). This echoes the recently recognized 
epidemiological evidence that NAFLD/NASH-related HCC often develops in the liver with 
earlier-stage fibrosis (Kawada et al., 2009). Annual HCC incidence rate was nearly 4-fold 
higher in patients with high-risk prediction (41%/year) compared to low-risk prediction 
(11%/year) (Table S1). The prognostic association remained significant for each etiology 
subgroup in multivariable Cox regression adjusted for known clinical prognostic variables 
(Figure 1C). Of note, the prognostic association was significant in the subgroup of NASH 
patients (p=0.03), but not in NAFLD patients (p=0.14) in multivariable Cox regression. This 
indicates that presence of inflammation, i.e., steatohepatitis, is critical for the gene signature 
to be prognostic, and there is a need for complementary prognostic indicators for NAFLD 
patients who lack hepatic inflammation. Collectively, the results support panetiology 
prognostic capability of the gene signature assay in patients affected with HCV, HBV, 
alcohol, or NASH.
HCC risk prediction after pharmacological HCV eradication
The recent emergence of directly acting-antiviral regimens (DAAs) for HCV has enabled 
high rates of complete viral eradication, i.e., sustained virologic response (SVR) (Chung and 
Baumert, 2014). Although SVR was epidemiologically associated with reduced HCC 
incidence in patients with advanced fibrosis, the risk of HCC is not eliminated and persists 
beyond a decade even after achieving an SVR (Morgan et al., 2013; van der Meer et al., 
2012). Therefore, HCC risk prediction after SVR is urgently needed. Among the validation 
cohort (Cohort 5) patients infected with HCV (n=67), 4 patients achieved SVR prior to HCC 
development and showed relatively lower risk pattern of the HCC risk signature (Figure 1D), 
suggesting that SVR could modulate the molecular cancer risk status of the liver measured 
by the signature. Therefore, we next asked whether a change in the HCC risk gene signature 
expression after SVR is associated with future HCC risk by analyzing paired liver biopsy 
specimens obtained before and after antiviral therapy from 34 patients who never had HCC 
(median time from the second biopsy to the last observation: 6.0 years, IQR: 5.1–7.8 years). 
The magnitude of gene signature reversal, i.e., suppression of the HCC high-risk genes and 
restoration of the HCC low-risk genes in the signature, was the largest in 13 SVR subjects 
free of HCC at the end of follow-up (Figure 1E). Of note, 14 SVR patients who 
subsequently developed HCC showed less gene signature reversal even when compared to 
non-responders (NR) who did not develop HCC. Despite unsuccessful anti-HCV treatment, 
4 out of the 5 HCC-free NR patients achieved resolution of clinically active hepatitis, i.e., 
normalization of elevated hepatic transaminases so-called biochemical response, which was 
associated with reduced HCC risk (Hoshida et al., 2014), consistent with the larger gene 
signature reversal. In contrast, the SVR patients who had HCC similarly achieved 
Nakagawa et al. Page 5













normalization of transaminases, suggesting that the persisting HCC risk post SVR is not due 
to continued hepatic inflammation, but due to other unknown factors, which can be 
quantified by the HCC risk gene signature. These results collectively suggest that the gene 
signature assessment could be a promising quantitative HCC risk predictor after HCV 
eradication.
Global transcriptomic landscape of fibrotic human livers
We next explored pan-etiology targets of HCC chemoprevention by determining the 
systems-level dysregulation of the fibrotic/cirrhotic liver transcriptome. Regulatory gene 
network modeling was performed by synthesizing genome-wide transcriptome profiles of 
clinical fibrotic/cirrhotic liver tissues generated in our previous studies (Hoshida et al., 2008; 
Hoshida et al., 2013) (Cohort 1–3, n=523 in total, Figures 2A and S2A). Gene co-expression 
meta-analysis followed by Planar Filtered Network Analysis (PFNA) identified 31 tightly 
co-regulated gene modules, forming 2 major groups connected by 3 central hub modules 
(no.2, 3, and 8) (Figure 2B). Molecular pathways/functions, which have been implicated in 
the pathogenesis of liver inflammation, fibrogenesis, and carcinogenesis, were identified in 
the modules (Table S2). Gene module no.14, which was enriched with growth signaling 
pathways, contained the EGF pathway, which we identified as an HCC chemoprevention 
target in our previous study (Fuchs et al., 2014), which was directly connected to one of the 
central hub modules, suggesting a close regulatory relationship between them. Interestingly, 
the HCC risk gene signature was associated with known cancerous conditions in multiple 
organs such as colon mucosa affected with ulcerative colitis (but not Crohn’s disease, 
consistent with clinical observation), actinic keratosis (a precursor lesion of non-melanoma 
squamous cell carcinoma caused by long-term sun exposure), and diabetes (Calle et al., 
2003; Itzkowitz et al., 2005) (Tables S3 and 4 and Figures S2B–E). Transforming growth 
factor-β (TGF-β), which was enriched in the stress response/RhoA module (no. 3), was 
inferred as a common top upstream regulator of the cross-organ carcinogenic gene 
dysregulations together with other cytokine-encoding genes, e.g., TNF and IL6 (Table S5), 
which indeed induced the HCC risk gene signature in lung epithelial cell line and 
organotypic ex vivo culture of non-diseased human liver tissues (Figures S2F and G). 
Indeed, RHOA is a transcriptional target of the TGF-β pathway (see “Transcriptional targets 
of TGF-β pathway activation” in Supplemental Experimental Procedures).
In human cirrhosis, the gene modules of stress response (no.2 and 3), extracellular matrix 
(ECM) (no.19), and interferon (no.24 and 28) were strongly induced, whereas the hepatocyte 
modules (no.9, 22, 23, and 26) were suppressed (Figure 3, Table S6). Several chemically, 
physiologically, or genetically-induced rodent models of liver fibrosis and/or HCC 
recapitulate the dysregulation of the HCC risk gene signature and the cirrhosis gene modules 
to varying degrees, underscoring their utility in testing chemoprevention strategies targeting 
specific gene module dysregulation. The repeated, low-dose diethylnitrosamine (DEN)-
induced cirrhosis-driven HCC rat (low-dose DEN rat) is one of the models that showed the 
most striking induction of the HCC risk gene signature and global similarity in dysregulation 
of the cirrhosis gene modules. In this model, transcriptome profiles of hepatocyte and 
hepatic stellate cell fractions showed that the pattern of gene module dysregulation was 
generally comparable, suggesting the presence of intensive cross-talks between the cell 
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types, while induction of the growth signaling module and stress response/ECM modules 
was relatively stronger in hepatocytes and hepatic stellate cells, respectively. Therapeutic 
modulation, i.e., reversal of the dysregulated HCC risk gene signature and the cirrhosis gene 
modules, could also be monitored for anti-fibrotic and/or HCC chemopreventive treatments, 
including a small molecule EGF receptor inhibitor erlotinib (Fuchs et al., 2014), 
epigallocatechin gallate (EGCG, a green tea polyphenol), ghrelin (a “hunger” hormone), and 
vitamin D, depicting the utility of monitoring the cirrhosis gene modules in assessing 
clinical relevance of experimental HCC chemoprevention therapies.
Computational identification of LPA pathway as a functional key regulator of cirrhosis-
driven carcinogenesis
In human cirrhosis, the central hub module, no.8, which is located at the center of the global 
cirrhosis gene networks, was the only module uniquely activated in association with 
increased risk of future de novo HCC recurrence, but not with presence of cirrhosis (Figure 
3, the second column compared to the first column from the left), which suggested its 
specificity to carcinogenesis and reasoned us to explore the drivers of carcinogenesis in the 
module. In fact, computationally inferred hub key driver genes in the module and tightly-
connected neighboring modules, no.2 and 3, were enriched with genes implicated in 
carcinogenesis: HINT1 has been described as a tumor suppressor gene in HCC (Calvisi et 
al., 2009; Zhang et al., 2009), UBE2K encodes an E2 ubiquitin ligase involved in p53 
degradation (Saville et al., 2004), YY1 encodes an oncogenic transcription factor in HCC 
that is also known to suppress p53 pathway (Gordon et al., 2006), and ATP5J2, which 
encodes a protein known to physically interact with c-Myc (Figure 4A) (Agrawal et al., 
2010). Indeed, HIP2 and YY1 expression was negatively correlated with p53 activation 
status, and ATP5J2 expression was positively correlated with induction of Myc pathway 
target genes in the 3 human fibrosis/cirrhosis cohorts (Cohort 1–3, Figures S3A–C). RHOA 
was another hub gene of the module no.3 together with its known target MRCL3, encoding 
myosin regulatory light chain, as well as fibrosis-related genes such as CCL5 (Berres et al., 
2010) (Figure 4A).
To identify functional regulators of the genes in module no.8, we systematically surveyed 
enrichment of experimental genetic perturbation transcriptome signatures defined by shRNA 
library-based knockdown of 5,272 genes in an unbiased manner (the transcriptome 
signatures were generated using the dataset from NIH Library of Integrated Cellular 
Signatures [LINCS] project, www.lincsproject.org) (see Supplemental Experimental 
Procedures). Top enriched upstream regulator genes were AKT1, SLC35A1, DDX42, 
LPAR1, and ILK (Figure 4B). Indeed, Akt/mechanistic target of rapamycin (mTOR)/
phosphoinositide 3-kinase (PI3K) pathway inhibitors, everolimus and sirolimus, are 
currently being tested in clinical trials for prevention of post-liver transplantation HCC 
recurrence (Burra and Rodriguez-Castro, 2015). Among the rest, LPAR1 was the only one 
encodes a protein selectively targetable with compounds currently under clinical 
development. Lysophosphatidic acid receptors (LPARs) form a family of G protein-coupled 
receptors, and LPAR1 has been shown to promote fibrosis in multiple organs by 
upregulating pro-fibrogenic mediators, including connective tissue growth factor (CTGF), 
known to be elevated in activated hepatic stellate cells (Huang and Brigstock, 2012; Pradere 
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et al., 2007; Sakai et al., 2013; Tager et al., 2008). In liver, expression of autotaxin (ATX), 
which converts lysophosphatidylcholine (LPC) into LPA (ligand for LPAR), is elevated in 
serum of HCV-infected patients, especially in those with HCC and/or severe fibrosis 
(Cooper et al., 2007; Nakagawa et al., 2011; Watanabe et al., 2007). In consistent, AKAP13, 
an HCC risk signature member gene, encodes a guanine exchange factor that relays the 
signal to downstream of the RhoA signaling pathway, further supporting the role of LPA 
pathway as a functional driver of HCC development.
It is known that RhoA, Ras/mitogen-activated protein kinase kinase (MAPK)/extracellular 
signal–regulated kinase (ERK)/MAPK/ERK kinase (MEK), Akt/PI3K, and phospholipase C 
(PLC) pathways are downstream effectors of the LPA pathway (Kihara et al., 2015). In 
Cohort 5, expression of NCAPH (RhoA pathway target), PRKG2 (K-Ras pathway target), 
SERPINB2 (H-Ras pathway target), and GPX2 (MEK pathway target) gradually increased 
according to the HCC risk signature-based stratification (Figure S3D). Transcriptome-based 
unbiased in silico screening of 20,413 chemical perturbation in the LINCS database using 
the HCC risk gene signature as a query yielded selective inhibitors of Rho kinase, Akt/PI3K, 
and MAPK/ERK/MEK pathways, further supporting the involvement of the LPA 
downstream pathways (Table S7). These results collectively support that the LPA pathway 
activation is robustly observed in human and rodent cirrhotic livers at risk of HCC 
development, representing an HCC chemoprevention target.
In vivo pharmacological LPA pathway inhibition suppressed HCC development, and 
reversed HCC risk gene signature
We next examined HCC chemopreventive effects of LPA pathway inhibition by using 
selective ATX (AM063) and LPAR1 (AM095) inhibitors (Figure S4A). To examine 
involvement of the RhoA pathway, two Rho kinase (ROCK) inhibitors, Fasudil and Y-27632, 
were tested in a fibrogenic human hepatic stellate cell line, TWNT-4, along with AM095. 
All of the three compounds similarly suppressed LPA-induced phosphorylation of myosin 
regulatory light chain (pMRLC), indicator of RhoA pathway activation (Figure S4B). 
Suppression of pERK (downstream of another LPA target, MEK/Ras pathways), was unique 
to AM095, consistent with the established specificity of the compound to the LPA pathway 
(Stein et al., 2015; Swaney et al., 2011). In contrast, pAkt was suppressed by LPA pathway 
activation and restored by AM095, suggesting that the Akt and LPA pathways are in 
negative feedback with each other in the liver, and LPA signaling represents an HCC 
chemoprevention target distinct from the Akt pathway. TGF-β is one of the major pro-
fibrogenic factors in the liver, which has been extensively studied as a potential therapeutic 
target and is known as an upstream regulator of CTGF (Hoshida et al., 2014). TGF-β 
neutralizing antibody had no effect on the LPA downstream pathways. LPA-induced CTGF 
expression was suppressed by AM095 and, to a lesser extent, Y-27632 whereas TGF-β 
neutralizing antibody had no effect (Figure S4C). shRNA-based knockdown of LPAR1 and 
RHOA expression resulted in similar suppression of LPA-induced CTGF expression 
(Figures S4D and E).
In the low-dose DEN rat model of cirrhosis-driven HCC, which manifests global 
transcriptomic and histological similarity to human (Fuchs et al., 2014) (Figures 3 and S4F), 
Nakagawa et al. Page 8













plasma ATX activity and hepatic Lpar1 expression gradually increased as cirrhosis 
developed (Figures 5A–5C). Hepatic Ctgf expression similarly increased mainly in hepatic 
stellate cell fraction (Figure S4G). Atx expression was higher in the hepatocyte fraction, 
whereas Lpar1 were expressed predominantly in the stellate cell fraction, collectively 
suggesting that cross-talk between the cell types results in the LPA pathway activation in the 
liver tissue (Figure S4H). Ten-week administration of AM063 or AM095 significantly 
reduced hepatic expression of Ctgf, collagen 1 (Col1a1), and α-smooth muscle actin (α-
SMA, Acta2), the major extracellular matrix proteins secreted from activated hepatic stellate 
cells (Figure S4I). Histological liver fibrosis was attenuated and, as bioinformatically 
predicted, HCC nodules were significantly reduced (Figures 5C–F). Correspondingly, 
transcriptome profiling of the rat livers by RNA-Seq demonstrated reversal of the HCC risk 
gene signature and dysregulation of human cirrhosis gene modules along with the LPA 
downstream pathways and the hepatic stellate cell gene signature (Zhang et al., 2016) 
(Figure 5G). The driver genes of the hub cirrhosis gene modules (no.2, 3, 8) and EGF 
pathway targets were suppressed by the compounds, whereas modulation of TGF-β pathway 
targets was moderate (Figure S4J). In summary, the pharmacological LPA pathway 
inhibition elicited HCC chemopreventive effect via suppression of RhoA and ERK 
pathways, but not Akt and TGF-β pathways. Neither of the compounds showed evidence of 
hepatotoxicity, while decreased serum levels of bilirubin was observed consistent with the 
histological improvement of liver fibrosis (Figure S4K).
HCC risk gene signature reversal by LPA pathway inhibition in organotypic ex vivo culture 
of human fibrotic liver tissues
Finally, we sought to determine whether the reversal of the HCC risk gene signature, which 
was accompanied with the in vivo HCC chemopreventive effect by LPA pathway inhibition, 
can be monitored in human liver tissues. We first confirmed that induction of the HCC risk 
gene signature as well as our hepatic stellate cell signature (Zhang et al., 2016) was 
preserved in organotypic ex vivo culture of carbon tetrachloride-induced fibrotic mouse liver 
tissue up to 48 hr, even without continued chemical treatment, suggesting that fibrotic tissue 
microenvironment is sufficient for perpetuation of the gene signature induction in the culture 
(Figure S5A). Subsequently, 13 clinical human liver tissues (male: 7, female: 6; HBV: 5, 
HCV: 3, NASH: 1, and cryptogenic: 4) were similarly cultured ex vivo with AM095 for 48 
hr. HCC risk gene signature prediction was performed using the tissues before culture 
(Figures 6 and S5B). With the drug treatment, varying degrees of HCC high-risk gene 
suppression, HCC low-risk gene restoration, and/or combinatorial reversal were observed 
(Figure 6). The presence of HCC high-risk gene signature before the drug treatment 
(p=0.008, Wilcoxon rank-sum test) as well as less liver fibrosis (p=0.01, Pearson correlation 
test) were associated with greater gene signature reversal, suggesting that these factors may 
predict gene signature response to AM095 in actual clinical setting. At gene and molecular 
pathway levels, suppression of growth signaling (EGF, IGFBP6, EPHA4), extracellular 
matrix protein-encoding genes (COL6A3, COL16A1, LOXL2), cell adhesion and fibrogenic 
cytokines (LPP, PODXL, CTNND2, CXCR4, CCL21) and oxidative stress (GPX2, NOS2A) 
as well as restored expression of plasma protein-encoding genes (PLG, C8B, C5, TTR) were 
the main features observed in the gene signature responders. The hepatic stellate cell 
signature was suppressed in patients with reversed HCC risk gene signature (p=0.045, 
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Wilcoxon rank-sum test). These results suggest that the HCC risk gene signature or serum 
LPA level or proteomic surrogates of the tissue-based gene signature (Cooper et al., 2007; 
Muir et al., 2013; Nakagawa et al., 2011; Watanabe et al., 2007) could serve as a companion 
biomarker for pharmacological LPA pathway inhibition to identify potential responders and 
monitor the therapeutic effect in future HCC chemoprevention trials. In fact, when 
enrollment in adjuvant chemoprevention trials following curative treatment is limited to 
subjects with the HCC high-risk gene signature, the estimated sample size is comparable to 
those required in cancer therapeutic trials, i.e., up to a few hundred (Figure S5C).
DISCUSSION
Cancer chemoprevention is a major unmet medical need with numerous challenges during 
both preclinical and clinical development (Hoshida et al., 2014). It is typically not feasible to 
experimentally model the entire physiological process of cancer development in order to 
evaluate the effect of cancer-preventive intervention. Cancer chemoprevention clinical trials 
enrolling cancer-free asymptomatic individuals require larger sample sizes and longer 
follow-up time compared to advanced-stage cancer therapeutic trials due to a smaller event 
rate (Lippman et al., 2009). Even when clinical risk factors are known, thousands of 
individuals are generally required to be enrolled and followed for longer than 5 years to 
detect cancer preventive effect (Cuzick et al., 2014). Therefore, molecular biomarkers of 
cancer risk that further enrich high-risk population will lower the bar to conducting cancer 
chemoprevention trials. Our HCC risk signature, which was validated in all major HCC 
etiologies including post HCV cure, will have a wide range of applicability as a pan-etiology 
companion biomarker for HCC chemoprevention clinical trials.
The cirrhosis gene regulatory modules provide a systems-level landscape of molecular 
dysregulation common to a wide range of liver disease etiologies. Projection of the global 
transcriptome onto the cirrhosis gene module map will enable rapid and straightforward 
identification of experimental models that best resemble human cirrhosis according to the 
molecular targets of interest. Our study demonstrates that the LPA pathway is one of the 
central regulators of human cirrhosis pathogenesis and a promising target for HCC 
chemoprevention, one made more feasible by the existence of compounds in clinical 
development for non-cancer patients with negligible toxicity (Kihara et al., 2015). Although 
TGF-β pathway has been studied as an anti-fibrosis target, clinical inhibition of the pathway 
has been deemed challenging due to systemic toxicities and may not be justified as a 
preventive intervention for asymptomatic and still cancer-free individuals (Hoshida et al., 
2014; Mehal and Schuppan, 2015). Our results suggest that LPA pathway inhibition is an 
alternative way to antagonize downstream targets to achieve HCC chemoprevention, while 
circumventing the toxicities of directly targeting TGF-β pathway.
Collectively, our study demonstrates that transcriptome analysis of cancer-prone, 
chronically-diseased organs with long-term clinical observation is a viable and effective 
approach to uncover cancer chemoprevention biomarkers and targets. This approach will be 
widely applicable to other cancer types driven by chronic organ inflammation and/or 
fibrosis, as a paradigm, reverse-engineering precision cancer prevention.
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More detailed procedures are described in the Supplemental Information.
Patient cohorts
Prognostic association of the HCC risk gene signature was validated in an independent 
cohort of 263 consecutive patients with curatively resected HCC at Toranomon Hospital or 
Kumamoto University Hospital between 1988 and 2012. Paired liver biopsy tissues were 
obtained before and after anti-HCV therapy for patients with chronic hepatitis C at 
Toranomon Hospital and Kaohsiung Medical University Hospital between 2004 and 2009. 
The study was approved by institutional review board (IRB) at Mount Sinai Hospital, 
Toranomon Hospital, Kumamoto University Hospital, and Kaohsiung Medical University 
Hospital for anonymous analysis of de-identified archived waste FFPE tissues from previous 
routine clinical care without written informed consent.
HCC risk gene signature profiling
Archived FFPE liver tissues were analyzed by the 32-gene HCC risk signature (King et al., 
2015) implemented in nCounter Elements assay (NanoString). Prognostic prediction was 
performed as previously described (King et al., 2015). Prognostic association of the gene 
signature was evaluated by log-rank test and multivariable Cox regression modeling adjusted 
for clinically well-established prognostic variables. All analyses were performed using R 
statistical language (www.r-project.org) and GenePattern (www.broadinstitute.org/
genepattern).
Human cirrhosis regulatory gene modules
Functionally co-regulated gene modules in human fibrotic/cirrhotic liver tissues were 
determined in genome-wide transcriptome profiles of 3 independent patient cohorts (n=523) 
using Fisher’s inverse chi-square statistic (Fisher, 1932) and Planar Filtered Network 
Analysis (PFNA) algorithm (Song and Zhang, 2015). Induction or suppression of the gene 
modules as was assessed in a panel of in vitro and in vivo experimental models of liver 
diseases and HCC (Table S6) using Gene Set Enrichment Analysis (GSEA) (Subramanian et 
al., 2005).
In vitro and in vivo pharmacological LPA pathway inhibition
The ATX inhibitor AM063 and the LPAR1 antagonist AM095 were provided by Amira 
Pharmaceuticals and Bristol Myers Squibb, and tested in human hepatic stellate cell line, 
TWNT-4, and male Wistar rats (Charles River) treated with low-dose (50 mg/kg) weekly 
injection of diethylnitrosamine (DEN) as previously described (Fuchs et al., 2014) following 
Guide for the Care and Use of Laboratory Animals (National Academy of Sciences) and the 
institutional guidelines, and the protocol was approved by Massachusetts General Hospital 
Subcommittee on Research Animal Care. Tumor nodules were counted in serial liver 
sections, and primary hepatocytes and hepatic stellate cells were isolated from fresh liver 
tissue using an established protocol (Fuchs et al., 2014). Gene expression was measured by 
real-time PCR. Total/phosphorylated MRLC, collagen 1, and α-SMA protein levels were 
determined by western blotting as previously described (Fuchs et al., 2014). Liver fibrosis 
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stained by sirius red was quantified using Image J software (imagej.nih.gov/ij) as collagen 
proportionate area. Intergroup difference was evaluated by t-test with Bonferroni correction 
as needed.
Organotypic ex vivo culture of experimental and clinical liver tissues
Fresh liver tissues from carbon tetrachloride (CCl4)-treated strain A/J male mice (Jackson 
Laboratory) and de-identified surgically resected human liver tissues (obtained via Mount 
Sinai Biorepository with IRB-approved written informed consent) were sliced into 300 µm-
thick tissue sections, and the human livers were cultured with the LPA pathway inhibitor 
AM095 (3 µM) or DMSO for 48 hr. Expression of HCC risk gene signature was determined 
before and after the culture using the Elements assay, and modulation of the signature by 
AM095 was determined by GSEA.
Transcriptome profiling of rodent livers
Transcriptome profiling of rodent liver was performed by RNA-Seq, RatRef-12 beadarray, 
or MouseRef-8 beadarray (Illumina) as previously described (Fuchs et al., 2014). Rodent 
genes were converted into orthologous human genes using a mapping table obtained from 
NCBI HomoloGene database (build 68). Induction or suppression of target genes of relevant 
cellular signaling pathways was assessed by GSEA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Chronically inflamed and/or fibrotic organ is a clinically well-known “soil” that develops 
cancer, although it has been challenging to identify clinically relevant cancer 
chemoprevention targets in the organ and therapies due to complex molecular 
dysregulation involving multiple cell types, lengthy process of carcinogenesis, and the 
lack of cancer risk biomarkers to enable their clinical testing. Here we show a strategy to 
systematically utilize diseased organ transcriptome to simultaneously identify clinically 
relevant cancer chemoprevention biomarkers, targets, and therapies by integrating clinical 
cancer risk based on several decades of clinical observation. This approach is applicable 
to other cancer types arisen from chronically diseased organs, and will facilitate 
development of molecular targeted cancer chemoprevention therapies.
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• Clinically applicable pan-etiology HCC risk biomarker was 
established.
• Global transcriptome map of cirrhosis identified HCC chemoprevention 
targets.
• Global transcriptome map of cirrhosis identified clinically-relevant 
animal models.
• LPA pathway inhibitors were verified as HCC chemopreventive and 
antifibrotic drugs.
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Nakagawa et al. establish an hepatocellular carcinoma (HCC) risk gene signature 
applicable to all major HCC etiologies and identify the lysophosphatidic acid pathway as 
a central chemoprevention target, pharmacological inhibition of which reduces tumors 
and reverses the gene signature in preclinical models.
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Figure 1. HCC risk gene signature in the major HCC etiologies
(A) Heatmap of the 32-gene HCC risk gene signature, which classified the patients (n=263) 
into high-, intermediate-, and low-risk groups as indicated as orange, gray, and green color 
bars, respectively. Black bars on top indicate presence of each HCC etiology.
(B) Probabilities of HCC (left) and overall survival (right) according to the gene signature-
based HCC risk prediction. p values were calculated by log-rank test.
(C) Hazard ratios of HCC development according to HCC etiology in multivariable Cox 
regression modeling adjusted for clinically-established risk factors. Blue squares indicate 
hazard ratios, and horizontal bars indicate corresponding 95% confidence interval. BCLC 
stage, Barcelona Clinic Liver Cancer prognostic stage.
(D) Expression pattern of HCC risk gene signature in a subgroup of patients with HCV 
infection (n=67). Black bars indicate patients who achieved sustained virologic response 
(SVR) to anti-HCV therapy prior to HCC development.
(E) HCC risk gene signature in paired liver biopsies obtained before and after anti-HCV 
therapy in patients with chronic hepatitis C who achieved no response (NR) or SVR and 
subsequently developed HCC or remained HCC-free. Magnitude of signature change is 
presented as normalized enrichment score (NES) computed by Gene Set Enrichment 
Analysis. Values attached to each bar indicates false discovery rate (FDR).
See also Figure S1 and Table S1.
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Figure 2. Human liver cirrhosis regulatory gene modules for discovery of HCC chemoprevention 
targets
(A) Transcriptomic meta-analysis of clinical liver fibrosis/cirrhosis cohorts to identify 
regulatory gene modules and putative key driver genes. Gene-gene correlation matrices in 
three human cirrhosis cohorts (left), synthesized gene-gene correlation matrix by using 
Fisher’s inverse chi-square statistic (middle), and workflow to identify regulatory gene 
modules and key driver genes (right) are shown. Rows and columns in the heatmaps 
represent genes in each cohort.
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(B) A graphical presentation of the 31 gene modules identified by Planar Filtered Network 
Analysis (PFNA) algorithm. Each node represents a gene colored according to assigned 
gene module. NF-κB: nuclear factor κ-B, TGF-β: transforming growth factor-β, GPCR: G 
protein-coupled receptor, PDGF: platelet-derived growth factor, mTOR: mechanistic target 
of rapamycin.
See also Figure S2 and Tables S2, S3, S4, and S5.
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Figure 3. Cross-species/model comparison in the space of human cirrhosis regulatory gene 
modules
Activation status of each cirrhosis gene module was assessed by Gene Set Enrichment 
Analysis, and visualized as gene set enrichment index (GSEI) calculated from gene set 
enrichment p value based on iterative random gene permutations (1,000 times for each 
module in each condition). Orange and green colors in heatmap indicate statistical 
significance of induction and suppression of each gene module, respectively, in association 
with each phenotype or intervention in each model. GSEI of +3 indicates induction (orange) 
at enrichment p=0.001, GSEI of −3 indicates suppression (green) at enrichment p=0.001, 
and GSEI of 0 indicates no modulation (white) at enrichment p=1.0. In “Cirrhosis (human)” 
column, genes in the transcriptome dataset were rank-ordered according to differential 
expression between cirrhotic and healthy livers to compute GSEI. In “HCC high risk 
(human)” column, genes were rank-ordered according to association with time to HCC 
development measured by Cox score (Hoshida et al., 2008) to compute GSEI. DEN, 
diethylnitrosamine; CCl4, carbon tetrachloride; BDL, bile duct ligation; MCD, methionine/
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choline-deficient diet, HFD, high fat diet; HCD, high cholesterol diet; FLS, fatty liver 
Shionogi; HSC, hepatic stellate cell; LEC, liver endothelial cell; EGCG, epigallocatechin 
gallate.
See also Table S6
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Figure 4. Bioinformatic identification of HCC chemoprevention targets
(A) Central hub gene modules no.2, no.3, and no.8 in human liver fibrosis/cirrhosis gene 
networks. Co-regulatory gene modules at the center of human liver fibrosis/cirrhosis 
regulatory gene networks determined by Planer Filtered Network Analysis (PFNA) in the 
genome-wide transcriptome profiles of 523 fibrotic/cirrhotic liver tissues (Cohort 1–3). 
Outline color of each node (gene) indicates gene module the gene belongs to (green, no.2; 
cyan, no.3; pink, no.8). Node color indicates correlation with HCC risk measured by Cox 
score in Cohort 1, from which the HCC risk gene signature was originally derived (red and 
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blue colors indicate correlation with high and low HCC risk, respectively). Node size 
reflects connectivity to neighboring genes measured by degree. Putative key driver genes 
identified by Key Driver Analysis (KDA) are labeled with gene symbol.
(B) Functional regulators of the HCC risk-associated gene module (no.8). Enrichment of 
experimental genetic perturbation transcriptome signatures defined by shRNA library-based 
knockdown of 5,272 genes (down-regulated gene signatures by the gene knockdown) 
derived from NIH Library of Integrated Cellular Signatures (LINCS) project 
(www.lincsproject.org) in the HCC risk-associated gene module, no.8, was systematically 
assessed in an unbiased manner using Fisher’s exact test with FDR correction. Genes are 
rank-ordered according to significance of enrichment (Fisher’s exact test false discovery 
rate), and top 5 genes are indicated with gene symbols.
See also Figure S3 and Table S7.
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Figure 5. LPA pathway inhibition attenuated fibrosis progression and reduced HCC in cirrhosis-
driven HCC rat model
(A) Plasma autotaxin (ATX) activity over time during liver fibrosis progression in low-dose 
diethylnitrosamine (DEN) rat compared to control animals treated with PBS.
(B) Hepatic lysophosphatidic acid receptor 1 gene (Lpar1) expression (normalized to Actin) 
over time during liver fibrosis progression.
(C) Macroscopic images of the livers and tumors, H & E staining (arrow heads indicate 
tumor, scale bar indicates 100 µm), trichrome stain of fibrosis (scale bar indicates 250 µm), 
and α-smooth muscle actin (SMA) (marker of activated hepatic stellate cells, scale bar 
indicates 250 µm).
(D) Change in collagen proportionate area by AM063 or AM095 treatment.
(E) Change in histological liver fibrosis score, Ishak score (Ishak et al., 1995), by AM063 or 
AM095 treatment.
(F) Change in number of HCC nodules by AM063 or AM095 treatment.
(G) Modulation of HCC risk gene signature, human cirrhosis gene modules, and LPA 
downstream pathways (RhoA/MEK/Ras pathways) by AM063 or AM095 in RNA-Seq 
transcriptome profiles of low-dose DEN rat livers. The heatmap shows gene set enrichment 
index (GSEI) calculated from gene set enrichment p value based on iterative random gene 
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permutations (1,000 times). GSEI of +3 indicates induction (orange) at enrichment p=0.001, 
GSEI of −3 indicates suppression (green) at enrichment p=0.001, and GSEI of 0 indicates no 
modulation (white) at enrichment p=1.0.
Each experiment was performed at least in three biological replicates, and the results are 
presented by mean and standard deviation (error bar). p values were calculated by t-test with 
Bonferroni correction.
See also Figure S4.
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Figure 6. HCC risk gene signature modulation by LPA pathway inhibition by AM095 in 
organotypic ex vivo culture of clinical fibrotic liver tissues
HCC risk gene signature prediction was determined using tissues before the treatment. 
Modulation of HCC risk gene signature and hepatic stellate cell signature by AM095 is 
presented as gene set enrichment index (GSEI). Modulation of the signature member genes 
is presented as log2-fold change compared to respective DMSO-treated controls. Orange and 
green colors in the upper heatmap indicate induction and suppression of gene signature by 
GSEI, respectively. GSEI of +3 indicates induction (orange) at enrichment p=0.001, GSEI of 
−3 indicates suppression (green) at enrichment p=0.001, and GSEI of 0 indicates no 
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modulation (white) at enrichment p=1.0. Read and blue colors in the lower heatmap indicate 
up- and down-regulation of gene expression, respectively.
See also Figure S5.
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